FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer.

Authors :: Kacew A
Sweis RF
Source :: Frontiers in immunology [Front Immunol] 2020 Nov 05; Vol. 11, pp. 575258. Date of Electronic Publication: 2020 Nov 05 (Print Publication: 2020).
Publication Year :: 2020
Abstract: FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.<br /> (Copyright © 2020 Kacew and Sweis.)